SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- Nanogen, Inc. , developer of advanced diagnostic products, will host a conference call on Wednesday, November 1, 2006 at 4:30 p.m. Eastern (1:30 p.m. Pacific) to discuss 2006 third quarter financial results. The financial results press release will be issued at close of market on November 1. Interested investors and others may participate in the conference call by dialing 877-407-9205 for US/Canada participants and 201-689-8054 for international participants.
(Logo: http://www.newscom.com/cgi-bin/prnh/20050803/LAW135LOGO )
Audio of management’s presentation will be available via live webcast on the investor relations section of Nanogen’s corporate website at www.nanogen.com, and will be archived for 90 days. A digital recording of the call will also be available for 48 hours, beginning two hours after the completion of the conference call on November 1, and can be accessed via telephone at 877-660-6853 for US/Canada participants and 201-612-7415 for international participants. The account number, 286, along with the conference ID, 218415, will be required to listen to the playback
About Nanogen, Inc.
Nanogen’s advanced technologies provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company’s products include real-time PCR reagents, the NanoChip(R) electronic microarray platform and a line of rapid, point-of-care diagnostic tests. Nanogen’s ten years of pioneering research involving nanotechnology holds the promise of miniaturization and continues to be supported for its potential for diagnostic and biodefense applications. For additional information please visit Nanogen’s website at www.nanogen.com .
Nanogen Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption “Factors That May Affect Results” and elsewhere in Nanogen’s Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20050803/LAW135LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comNanogen, Inc.
CONTACT: Robert Saltmarsh, Chief Financial Officer, +1-858-410-4600, orSuzanne Clancy, Corporate Communications, +1-858-410-4688, orsclancy@nanogen.com, both of Nanogen, Inc.; or Kim Richards, Media &Investor Relations of Porter Novelli Life Sciences, +1-619-849-5377, orkrichards@pnlifesciences.com, for Nanogen, Inc.
Web site: http://www.nanogen.com//
